{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:47:53Z","timestamp":1791668873304,"version":"4.3.4"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>We present a 67-year-old man with inoperable metastatic G3 NET of the pancreas. The lesions were intensely positive in [<jats:sup>68<\/jats:sup>Ga]Ga-DOTATOC PET\/CT and only weakly positive in the supplementary [<jats:sup>18<\/jats:sup>F]-FDG PET\/CT. Peptide receptor radionuclide therapy (PRRT) with [<jats:sup>177<\/jats:sup>Lu]Lu-DOTA-octreotate, after longstanding efficacy with repetitive retreatments over 7 years, eventually resulted only in disease stabilization without partial regression of lesions. After switching PRRT to the somatostatin receptor antagonist [<jats:sup>177<\/jats:sup>Lu]Lu-DOTA-LM3, a marked therapy response was observed, in remarkable contrast to the stable disease effect of <jats:sup>177<\/jats:sup>Lu-octreotate seen right before. This interesting image illustrates the superior therapeutic efficacy of somatostatin antagonist PRRT over agonist-based PRRT.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005938","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T01:00:15Z","timestamp":1745974815000},"page":"981-982","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Superior Response of CAP-PRRT of G3 NET When Switching to the Somatostatin Receptor Antagonist LM3: Intraindividual Proof-of-concept"],"prefix":"10.1097","volume":"50","author":[{"given":"Tilman","family":"Speicher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Burgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rosar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"R1-20250903","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00259-007-0688-7","article-title":"Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours","volume":"35","author":"van Essen","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R2-20250903","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00259-010-1631-x","article-title":"Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours","volume":"38","author":"Claringbold","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R3-20250903","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: from signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front Neuroendocrinol"},{"key":"R4-20250903","doi-asserted-by":"crossref","first-page":"16436","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","author":"Ginj","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R5-20250903","doi-asserted-by":"crossref","first-page":"e0195802","DOI":"10.1371\/journal.pone.0195802","article-title":"The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model","volume":"13","author":"Rylova","year":"2018","journal-title":"PLoS One"},{"key":"R6-20250903","doi-asserted-by":"crossref","first-page":"13973","DOI":"10.1073\/pnas.250483897","article-title":"SST3-selective potent peptidic somatostatin receptor antagonists","volume":"97","author":"Reubi","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R7-20250903","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","article-title":"First-in-humans study of the SSTR antagonist (177)Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety, and efficacy","volume":"62","author":"Baum","year":"2021","journal-title":"J Nucl Med"},{"key":"R8-20250903","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/diagnostics14090907","article-title":"Impressive response to TANDEM peptide receptor radionuclide therapy with (177)Lu\/(225)AcDOTA-LM3 somatostatin receptor antagonist in a patient with therapy-refractory, rapidly progressive neuroendocrine neoplasm of the pancreas","volume":"14","author":"Perrone","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"R9-20250903","first-page":"101","article-title":"First successful in-human application of 225Ac-DOTA-LM3 mono-PRRT for the treatment of an otherwise therapy-resistant neuroendocrine tumor (NET G3)","volume":"50","author":"Speicher","year":"2025","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T21:00:12Z","timestamp":1756933212000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005938","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"2025-01-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}